Emerging Drugs and Targets for Parkinson's Disease

Professor Martinez is a Research Professor at Instituto de Química Médica-CSIC. She has active research lines in the design and synthesis of new drugs for neurodegenerative diseases, searching for new targets to treat these devastating diseases. Currently, she ledas an interdisciplinary research group directed towards the discovery and development of new drugs for innovative targets in neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Amyotrophic lateral sclerosis or Multiple Sclerosis. Dr Gil obtained her PhD in Pharmaceutical Sciences from Universidad Complutense de Madrid before working with Prof. Dr. Stefan Bräse in the Kekulé Institute for Organic and Bioorganic Chemistry at the University of Bonn (Germany) where she was involved in the development of T1 triazene linker that has been successfully used as a linker for arenes. During this time she was a Marie Curie fellow of the European Union. She is currently working at the Instituto de Química Médica-CSIC, where she is responsible for the design and synthesis of biologically active organic molecules in the neurodegenerative field.

Overview on Parkinson disease. Rational for pharmacological intervention;

Dopaminergic pathway and L-Dopa treatments. Future challenges;

COMT Inhibitors: present problems and relevance of the new ones;

MAO inhibitors for PD (Safinamide);

Dopamine agonist: present and future (Pardoprunox);

Therapies for dopaminergic-induced dyskinesias in Parkinson disease. (Fipamizole);

Beyond the dopamine receptor: regulation of protein phosphatases;

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics;

Alpha-synuclein assembly as a therapeutic target of PD;

Alpha-synuclein (alpha-syn) phosphorylating polo-like kinase 2 (PLK2) as target for PD;

Hsp70 molecular chaperones and Parkinson's disease;

Glutamate receptors as therapeutic targets for Parkinson's disease;

Targeting adenosine A2A receptors in Parkinson's disease;

Leucine-rich repeat kinase-2 as target for Parkinson's disease;

Phosphodiesterase inhibitors for PD treatment;

P2X7 purinergic receptor: role in neurological disorders;

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease;

D3 dopamine receptor agonists: neuroprotection in Parkinson's disease;

Antioxidants and PD;

Tryptophan metabolism in Parkinson's disease;

Grafted neural stem cell-derived dopaminergic neurons for PD Therapy;

Gene therapy for Parkinson's disease;

Carotid body autotransplantation in Parkinson disease;Neurotrophic factor therapy for Parkinson's disease